Patent ID: 8101165
Filing Date: 2012-01-24
Classification: A61K,A61P

Abstract:
1. A pharmaceutical composition comprising: an immunogenic compound selected from the group consisting of: (i) an inactivated cytokine derived from a cytokine that naturally induces immunosuppression, cell apoptosis or angiogenesis, the said inactivated cytokine consisting of an inactivated TNFα that has been inactivated by a) subjecting native TNFα to a chemical treatment with formaldehyde and b) subjecting the treated TNFα obtained in step a) to a chemical treatment with glutaraldehyde; and (ii) an inactive peptide fragment comprising from 8 to 110 consecutive amino acids of a cytokine that naturally induces immunosuppression, cell apoptosis or angiogenesis, the said inactive peptide fragment consisting of a peptide fragment from TNFα that has been inactivated by a) subjecting a TNFα peptide fragment to a chemical treatment with formaldehyde and b) subjecting the treated TNFα peptide fragment in step a) to a chemical treatment with glutaraldehyde; and one or more pharmaceutical excipients.